Thymalfasin (thymosin alpha 1 (Ta1) peptide) is a thymus hormone polypeptide originally isolated as a natural substance from thymus tissue (thymosin fraction 5, a crude thymus gland extract). Thymalfasin is a pure, synthetic amino-terminal acylated peptide of 28 amino acids proteolytically processed from prothymosin alpha. It is used alone or with interferon as an immunomodulator for the treatment of chronic hepatitis B and hepatitis C. Thymalfasin is also used for the treatment of chemotherapy-induced immunosuppression and to enhance the efficacy of influenza and hepatitis B vaccines in immunocompromised patients.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Thymalfasin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.